Investview acquires Renu Labs and repurchases 121M shares (6.5% of outstanding)

Investview, Inc.

Acquired Renu Laboratories, a manufacturer of proprietary health/beauty/wellness products; terms not disclosed.
Expects acquisition to be revenue accretive as early as Q4 2024 - Q1 2025 via iGenius cross-selling.
Repurchased 121M shares (6.5% of outstanding) from three non-affiliate shareholders at a discount to closing price.
Repurchase resolves a dispute related to 2017 issuance; price payable in 10 equal quarterly installments.
Plans to operate Renu under new myLife Wellness business unit leveraging its FDA-registered, cGMP facility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.